LymphAG Cancer Research Results

LymphAG, Lymphangiogenesis: Click to Expand ⟱
Source: HalifaxProj(impede)
Type:
Lymphangiogenesis is the process of forming new lymphatic vessels from pre-existing ones. Lymphangiogenesis is regulated by a range of growth factors and molecular signals, including vascular endothelial growth factor-C (VEGF-C), vascular endothelial growth factor-D (VEGF-D), and angiopoietins. Dysregulation of lymphangiogenesis has been implicated in various diseases, including cancer, lymphedema, and inflammatory disorders.
Lymphangiogenesis is often upregulated in cancer, promoting the growth and spread of tumors. The expression of lymphangiogenic factors, such as vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor-D (VEGF-D), is increased in many types of cancer, including breast, lung, colon, and melanoma.
Scientific Papers found: Click to Expand⟱
8001- itraC,    Repurposing itraconazole as an anticancer agent
- Review, Var, NA
*AntiFungal↑, Itraconazole, a common anti-fungal agent, has demonstrated potential anticancer activity, including reversing chemoresistance mediated by P-glycoprotein,
AntiCan↑,
P-gp/ABCB1↓, itraconazole among patients with various types of cancer could not be explained by P-gp inhibition alone. R
HH↓, modulating the signal transduction pathways of Hedgehog, mechanistic target of rapamycin and Wnt/β-catenin in cancer cells, inhibiting angiogenesis and lymphangiogenesis, and possibly interfering with cancer-stromal cell interactions
mTOR↓,
Wnt↓,
β-catenin/ZEB1↓,
angioG↓,
LymphAG↓,
ChemoSen↑, survival advantage of combination chemotherapy for relapsed non-small cell lung, ovarian, triple negative breast, pancreatic and biliary tract cancer.
OS↑, 28 patients with biliary tract cancer received itraconazole, and subsequently experienced a median OS of 12 months
Gli1↓, Decreased GLI1 and Ki67 among vismodegib-naive 8 patients
Ki-67↓,
CSCs↓, Itraconazole may be a promising agent for targeting CSCs in relapsed disease of multiple types of cancer;


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   Gli1↓, 1,   HH↓, 1,   mTOR↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   LymphAG↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   OS↑, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: LymphAG, Lymphangiogenesis
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:176  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page